These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 24186136)

  • 1. Outcome of patients with micropapillary urothelial carcinoma following radical cystectomy: ERBB2 (HER2) amplification identifies patients with poor outcome.
    Schneider SA; Sukov WR; Frank I; Boorjian SA; Costello BA; Tarrell RF; Thapa P; Houston Thompson R; Tollefson MK; Jeffrey Karnes R; Cheville JC
    Mod Pathol; 2014 May; 27(5):758-64. PubMed ID: 24186136
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intratumoral heterogeneity of ERBB2 amplification and HER2 expression in micropapillary urothelial carcinoma.
    Isharwal S; Huang H; Nanjangud G; Audenet F; Chen YB; Gopalan A; Fine SW; Tickoo SK; Lee BH; Iyer G; Chadalavada K; Rosenberg JE; Bajorin DF; Herr HW; Donat SM; Dalbagni G; Bochner BH; Solit DB; Reuter VE; Al-Ahmadie HA
    Hum Pathol; 2018 Jul; 77():63-69. PubMed ID: 29601842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
    Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
    Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HER2 gene amplification occurs frequently in the micropapillary variant of urothelial carcinoma: analysis by dual-color in situ hybridization.
    Ching CB; Amin MB; Tubbs RR; Elson P; Platt E; Dreicer R; Fergany A; Hansel DE
    Mod Pathol; 2011 Aug; 24(8):1111-9. PubMed ID: 21516078
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of micropapillary urothelial carcinoma variant histology on survival after radical cystectomy.
    Fairey AS; Daneshmand S; Wang L; Schuckman A; Lieskovsky G; Djaladat H; Cai J; Miranda G; Skinner EC
    Urol Oncol; 2014 Feb; 32(2):110-6. PubMed ID: 23499168
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Outcomes following radical cystectomy for micropapillary bladder cancer versus pure urothelial carcinoma: a matched cohort analysis.
    Wang JK; Boorjian SA; Cheville JC; Kim SP; Tarrell RF; Thapa P; Frank I
    World J Urol; 2012 Dec; 30(6):801-6. PubMed ID: 23132611
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours.
    Fleischmann A; Rotzer D; Seiler R; Studer UE; Thalmann GN
    Eur Urol; 2011 Aug; 60(2):350-7. PubMed ID: 21640482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Stromal Lymphoid Response Status in Micropapillary Urothelial Carcinomas Diagnosed in Bladder Transurethral Resections and its Comparison with Conventional Urothelial Carcinomas.
    HacihasanoĞlu E; YÜcetaŞ U; OkÇu O; BehzatoĞlu K
    Turk Patoloji Derg; 2021; 37(1):26-31. PubMed ID: 32692402
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinicopathological Review of Micropapillary Urothelial Carcinoma.
    Kumar D; Adeniran AJ
    Curr Oncol Rep; 2022 May; 24(5):603-610. PubMed ID: 35199295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of Her2/neu in locally advanced bladder cancer: implication for a molecular targeted therapy].
    Wülfing C; von Struensee D; Bierer S; Bögemann M; Hertle L; Eltze E
    Aktuelle Urol; 2005 Sep; 36(5):423-9. PubMed ID: 16163605
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Micropapillary morphology is an indicator of poor prognosis in patients with urothelial carcinoma treated with transurethral resection and radiochemotherapy.
    Bertz S; Wach S; Taubert H; Merten R; Krause FS; Schick S; Ott OJ; Weigert E; Dworak O; Rödel C; Fietkau R; Wullich B; Keck B; Hartmann A
    Virchows Arch; 2016 Sep; 469(3):339-44. PubMed ID: 27392930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical significance of prominent retraction clefts in invasive urothelial carcinoma.
    Shah TS; Kaag M; Raman JD; Chan W; Tran T; Kunchala S; Shuman L; DeGraff DJ; Chen G; Warrick JI
    Hum Pathol; 2017 Mar; 61():90-96. PubMed ID: 27818288
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sociodemographic and survival disparities for histologic variants of bladder cancer.
    Jue JS; Koru-Sengul T; Moore KJ; Miao F; Alameddine M; Nahar B; Punnen S; Parekh DJ; Ritch CR; Gonzalgo ML
    Can J Urol; 2018 Feb; 25(1):9179-9185. PubMed ID: 29524972
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Transition between urothelial carcinoma in situ and non-invasive micropapillary carcinoma as a pivot connection between diverse morphologies of bladder carcinoma: a case report of urothelial carcinoma with villoglandular differentiation.
    Tajima S; Koda K
    Int J Clin Exp Pathol; 2015; 8(3):3288-93. PubMed ID: 26045854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Micropapillary urothelial carcinoma: clinico-pathologic review.
    Perepletchikov AM; Parwani AV
    Pathol Res Pract; 2009; 205(12):807-10. PubMed ID: 19767154
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overexpression of RNF2 Is an Independent Predictor of Outcome in Patients with Urothelial Carcinoma of the Bladder Undergoing Radical Cystectomy.
    Li XD; Chen SL; Dong P; Chen JW; Wang FW; Guo SJ; Jiang LJ; Zhou FJ; Xie D; Liu ZW
    Sci Rep; 2016 Feb; 6():20894. PubMed ID: 26869491
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients.
    Kamat AM; Dinney CP; Gee JR; Grossman HB; Siefker-Radtke AO; Tamboli P; Detry MA; Robinson TL; Pisters LL
    Cancer; 2007 Jul; 110(1):62-7. PubMed ID: 17542024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association of tumor-associated trypsin inhibitor (TATI) expression with molecular markers, pathologic features and clinical outcomes of urothelial carcinoma of the urinary bladder.
    Patschan O; Shariat SF; Chade DC; Karakiewicz PI; Ashfaq R; Lotan Y; Hotakainen K; Stenman UH; Bjartell A
    World J Urol; 2012 Dec; 30(6):785-94. PubMed ID: 21739120
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Micropapillary variant of urothelial carcinoma of the urinary bladder; a clinicopathological and immunohistochemical study.
    Samaratunga H; Khoo K
    Histopathology; 2004 Jul; 45(1):55-64. PubMed ID: 15228444
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of tyrosine kinase receptors HER2, EGFR, and VEGFR expression in micropapillary urothelial carcinoma with invasive urothelial carcinoma.
    Li J; Jackson CL; Yang D; Noble L; Wheeler M; MacKenzie D; Adegun T; Amin A
    Target Oncol; 2015 Sep; 10(3):355-63. PubMed ID: 25293577
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.